drugset / Trial / NCT02000609
A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of "Nexthaler" Dry Powder Inhaler in COPD Patients
RandomizedCrossoverDouble-blindTreatment
Summary
The study aim is to compare the pharmacodynamic effects (cardiovascular effects- primary variable: Heart rate over 4 hours post dosing- ) after administration of BDP and formoterol administered as CHF 1535 100/6 NEXThaler DPI or CHF1535 pMDI at two different dose levels.
Timeline
- Start
- 2013-12
- Primary completion
- 2014-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Formoterol | Other / unclassified | 12 ug | Inhaled |
| Comparator | Formoterol | Other / unclassified | 48 ug | Inhaled |
| Comparator | beclomethasone dipropionate | Other / unclassified | 200 ug | Inhaled |
| Comparator | beclomethasone dipropionate | Other / unclassified | 800 ug | Inhaled |